Table 2.
Interventions of patients with COVID-19.
| Total patients (n = 681) | Survivors (n = 577) | Non-survivors (n = 104) | P value | |
|---|---|---|---|---|
| Oxygen support | ||||
| Nasal cannula | 476 (70.1%) | 442 (76.9%) | 34 (32.7%) | 0.000 |
| Non-invasive ventilation | 164 (24.2%) | 125 (21.8%) | 39 (37.5%) | 0.001 |
| Invasive mechanical ventilation | 38 (5.6%) | 7 (1.2%) | 31 (29.8%) | 0.000 |
| Treatment | ||||
| Antiviral therapy | 666 (97.8%) | 566 (98.1%) | 100 (96.2%) | 0.380 |
| Arbidol | 571 (83.8%) | 500 (86.7%) | 71 (68.3%) | 0.000 |
| Ribavirin | 279 (41.0%) | 245 (42.5%) | 34 (32.7%) | 0.060 |
| Ganciclovir | 92 (13.5%) | 72 (12.5%) | 20 (19.2%) | 0.064 |
| Oseltamivir | 261 (38.4%) | 218 (37.8%) | 43(41.7%) | 0.446 |
| IFN-α | 119 (17.5%) | 96 (16.6%) | 23 (22.1%) | 0.176 |
| Antibiotic therapy | 571 (83.8%) | 470 (81.5%) | 101 (97.1%) | 0.000 |
| Glucocorticoids | 332 (48.8%) | 266 (46.2%) | 66 (63.5%) | 0.001 |
| Immunoglobulin | 372 (54.6%) | 305 (52.9%) | 67 (64.4%) | 0.029 |
| Vitamin C | 214 (31.4%) | 175 (30.3%) | 39 (37.5%) | 0.147 |
| Antifungal drugs | 19 (2.8%) | 10 (1.7%) | 9 (8.7%) | 0.000 |
IFN-α, Interferon-α;